Table 2.
Recurrent breast cancer treated with reirradiation.
| Pat. | Initial dose Gy | Reirrad. Dose (Gy) | Dose 1 +2 Gy | BED3 Gy | Interval (m) | Overlapping treatment volume | Chemo-therapy | Surgery for recurrence |
| 2 | 55 | 50,4 | 105,4 | 178,1 | 133,6 | Subpectoral + infraclavicular | 5-FU | Segmental resection (BCT) |
| 6 | 60,4 | 56 | 116,4 | 182,5 | 20,4 | Left thoracic wall | none | mastectomy, ax. diss. |
| 7 | 60 | 51,2 | 101,2 | 188,5 | 220,5 | Caudal thoracic wall | 5-FU | Local excision |
| 9 | 45 | 54,4 | 99,4 | 155,4 | 26,8 | Cranial thoracic wall | none | mastectomy, LN |
| 15 | 60 | 51,2 | 111,2 | 198,5 | 161,5 | Mastectomy scar | none | Thoracic wall resection, |
| 18 | 50 | 57,6 | 107,6 | 175,5 | 8,7 | lateral thoracic wall, ax. | none | Local excision |
| 19 | 60,4 | 61,2 | 121,6 | 194,6 | 42,8 | upper outer quadrant, ax. | Taxotere | resection, ax. diss. (BCT) |
| 23 | 60 | 50,4 | 110,4 | 180,6 | 135,1 | Left thoracic wall | none | reconstructive surgery |
| 24 | 60,4 | 55,8 | 116,2 | 185,9 | 42,5 | Mastectomy scar | Capecitab. | None |
| 25 | 60 | 50,4 | 110,4 | 180,6 | 212,6 | Left lower quadrant | none | Local excision (BCT) |
| 26 | 50 | 50,4 | 100,4 | 172,3 | 290,1 | Left thoracic wall | none | Thoracic wall resection |
| 27 | 50 | 46 | 96 | 160,0 | 114 | Right lower inner quadrant | none | Mastectomy post- reirradiation |
| 28 | 60 | 59,4 | 119,4 | 195,0 | 175,0 | Right upper quadrant | none | wide excision (BCT) |
| 1 | 50 | 50,4 | 100,4 | 164,0 | 184,7 | Lateral thoracic wall | none | none |
| 3 | 50,4 | 30 | 80,4 | 130,6 | 32,5 | Thoracic wall | Capecitab. | None |
| 4 | 60 | 45 | 105 | 172,0 | 23,5 | Thoracic wall | Capecitab. | None |
| 5 | 64 | 44,8 | 108,8 | 175,4 | 52,6 | Whole thoracic wall | Capecitab. | None |
| 8 | 60,4 | 50 | 110,4 | 180,0 | 85,9 | parasternal | none | None |
| 10 | 50,4 | 57,6 | 108 | 169,0 | 50,2 | Thoracic wall | 5-FU | None |
| 11 | 66,6 | 59,4 | 126 | 201,6 | 69,5 | Lat.thoracic wall | none | None |
| 12 | 50,4 | 45 | 95,4 | 152,6 | 8,7 | Thoracic wall, lateral | none | None |
| 13 | 60,0 | 50,4 | 110,4 | 180,6 | 49,9 | Upper quadrants | none | None |
| 14 | 60,4 | 50,4 | 110,8 | 177,3 | 28,7 | Upper outer quadrant | 5-FU | none |
| 16 | 55 | 49 | 104 | 186,6 | 185,2 | parasternal | none | None |
| 17 | 42,5 | 45 | 87,5 | 149,9 | 201,2 | supraclav., apex ax. | none | None |
| 20 | 50 | 48 | 98 | 163,3 | 32,7 | Sternal + infraclav. | Capecitab. | None |
| 21 | 59,4 | 44 | 103,4 | 168,4 | 53,1 | Thoracic wall | none | None |
| 22 | 59,4 | 46 | 105,4 | 177,7 | 20,0 | Thoracic wall | none | None |
| 29 | 50,4 | 50 | 100,4 | 164,0 | 31,1 | Thoracic wall | none | None |
Pat.: patient number ; BCT: breast conserving therapy for recurrence; LN: lymph nodes; ax. diss: axillary dissection; capecitab.: capecitabine.
Treatment details of recurrent breast carcinoma patients treated with reirradiation. Radiation doses (Gy) of initial radiotherapy and reirradiation, the cumulative dose (dose 1 + 2) and the cumulative BED3 Gy (Gy) are shown. For the initial treatment, whole breast plus boost dose is given, if retreatment volume included the initial boost volume. The interval between the last day of the initial radiotherapy and first day of reirradiation is given in months.